RATIONALE: @entity9 is characterised by hyperexcitability within nociceptive pathways that manifests behaviourally as @entity1931 and @entity1931 and remains difficult to treat with standard analgesics. However, antidepressants have shown reasonable preclinical and clinical anti-nociceptive efficacy against signs and symptoms of @entity9 . OBJECTIVES: To ascertain whether inhibition of @entity750 ( @entity750 ) and/or @entity1063 (NA) and/or @entity935 (DA) re-uptake preferentially mediates superior anti-nociception in @entity158 models. METHODS: The @entity750 re-uptake inhibitor @entity905 (3-30 mg/kg), the NA re-uptake inhibitor @entity18891 (3-30 mg/kg), the dual @entity750 and NA re-uptake inhibitor @entity906 (3-100 mg/kg) and the dual DA and NA re-uptake inhibitor @entity752 (3-30 mg/kg) were tested after intraperitoneal administration in @entity35 models of acute, persistent and @entity9 . RESULTS: @entity18891 and @entity906 dose-dependently attenuated second-phase flinching in the @entity406 test; @entity905 attenuated flinching only at the highest dose tested, whereas @entity752 was ineffective. In the @entity8638 ( @entity8638 ) and spinal nerve ligation models of @entity9 , hindpaw mechanical @entity1931 was significantly attenuated by @entity905 and particularly by @entity752 . @entity18891 and @entity906 were completely ineffective. In contrast, @entity18891 and @entity906 reversed thermal @entity1931 in @entity8638 @entity35 , whereas @entity752 and @entity905 were either minimally effective or ineffective. @entity905 , @entity18891 and @entity906 transiently increased the tail-flick latency in uninjured animals. Anti-nociceptive doses of drugs had no effect on motor function. CONCLUSIONS: Combined re-uptake inhibition of @entity750 and NA appears to confer a greater degree of anti-nociception in animal models of experimental @entity158 than single mechanism of action inhibitors. The selective attenuation of mechanical @entity1931 by @entity752 suggests that the additional re-uptake of DA may further augment @entity750 /NA re-uptake mediated anti-nociception after @entity128 .

Anti-nociception is selectively enhanced by parallel inhibition of multiple subtypes of monoamine transporters in @entity35 models of persistent and XXXX .

@entity1931 :: ('MESH:D006930', 'Disease') :: ['hyperalgesia', 'allodynia'] @entity905 :: ('MESH:D005473', 'Chemical') :: ['fluoxetine', 'Fluoxetine'] @entity935 :: ('MESH:D004298', 'Chemical') :: ['dopamine'] @entity406 :: ('MESH:D005557', 'Chemical') :: ['formalin'] @entity128 :: ('MESH:D020209', 'Disease') :: ['nerve injury'] @entity18891 :: ('MESH:C074679', 'Chemical') :: ['Reboxetine', 'reboxetine'] @entity750 :: ('MESH:D012701', 'Chemical') :: ['serotonin', '5-HT'] @entity158 :: ('MESH:D010146', 'Disease') :: ['preclinical pain', 'pain'] @entity35 :: ('10116', 'Species') :: ['rats', 'rat'] @entity906 :: ('MESH:C047426', 'Chemical') :: ['venlafaxine'] @entity752 :: ('MESH:D016642', 'Chemical') :: ['bupropion'] @entity1063 :: ('MESH:D009638', 'Chemical') :: ['noradrenaline'] @entity8638 :: ('MESH:D020208', 'Disease') :: ['chronic constriction injury', 'CCI'] @entity9 :: ('MESH:D009437', 'Disease') :: ['neuropathic pain', 'Neuropathic pain']
@entity9 :: (MESH:D009437,Disease) :: ['neuropathic pain']
